Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

Rapid now available for use in Mexico

Rapid grows international footprint and brings Mexico the only clinically validated, next-generation imaging platform for assessing ischemic stroke Menlo Park, Calif. —June 18, 2019 – iSchemaView, the worldwide leader in advanced imaging for stroke, has expanded its reach across North and Latin America, as the RAPID imaging platform is now available for use in Mexico. RAPID is designed to provide physicians with fully automated and easy-to-interpret imaging that facilitates timely clinical decision-making around stroke. "Strokes are a medical emergency, and urgent treatment is essential. The sooner a person receives treatment for a stroke, the less damage is likely to happen. That's why Punta Mita Hospital has acquired the most advanced cerebrovascular imaging platform available, RAPID,” offered Dr. Luis Alberto López Avelar, Medical Director Punta Mita Hospital. “We are committed to offering the best quality in medical care, which is why now with RAPID Punta Mita Hospital provides state-of-the-art technology for the timely and accurate diagnosis of a cerebrovascular event." Developed by leading stroke experts, RAPID technology has been selected for use in several ground-breaking trials that have changed treatment guidelines issued by both the American Heart Association and American Stroke Association. The RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID app or corporate partner workflow systems. The Complete RAPID Platform includes: RAPID CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time RAPID MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival RAPID CTA: automatically delivers CT angiography maps and identifies brain regions with reduced blood vessel density in 2D and 3D outputs RAPID ASPECTS: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury “Each day we work to transform stroke care, furthering our mission to provide healthcare professionals around the globe with the most comprehensive and intuitive suite of brain imaging solutions possible.” said Anil Singhal, MD, SVP, Worldwide Operations at iSchemaView. “Based on just the first quarter of this year, RAPID is already on pace to image over 132,500 patients in 2019, process over 250,000 scans and identify over 40,000 potential patients for thrombectomies. We will continue to expand, across Mexico and the globe, to provide as many hospitals as possible the tools they need to best help their patients and improve outcomes.” For more information about working with RAPID in Mexico, contact renatocunha@rapid.ai .
featured-image

Press Release

iSchemaView Launches Rapid U

New learning system and certification program sets international standard for professional status as a RAPID imaging practitioner. Empowers multiple members of stroke care teams to quickly become proficient. Menlo Park, Calif. —May 20, 2019 – iSchemaView, the worldwide leader in advanced imaging for stroke, has launched RAPID U, a training certification program for iSchemaView’s RAPID technology. An imaging standard around the world, RAPID is the platform designed to provide physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. Powered by a mobile-first learning management system, RAPID U provides role-based learning paths for various members of stroke care teams, including imaging technologists, stroke coordinators, neuroradiologists, neurologists and neurointerventionalists. The program is resource-rich for a robust education. It is enhanced with videos, case studies, publications, and clinical trials information across 15 courses, which cover all aspects of RAPID modules and products, and is supplemented with live sessions. "All aspects of the RAPID U certification program were developed by RAPID clinical and technology experts. It is unique, in that stroke care teams will be able to learn advanced imaging from the experts,” said Dr. Greg Albers, professor of Neurology at Stanford University, director of the Stanford Stroke Center and cofounder of iSchemaView. “iSchemaView is very excited to offer free RAPID certification to all customers via this new learning platform. As the availability of advanced stroke imaging continues to expand, it is vital for hospitals to have skilled individuals on their stroke care teams. RAPID U will help ensure that stroke care team members are fully trained on how to use RAPID effectively, and have a positive impact on patient outcomes.” RAPID U is accessible from the desktop and mobile apps. This allows the stroke team to take courses and obtain certificates at their own pace, when and where they choose. Clinicians can become RAPID certified following the successful completion of each course, and can have the option to continue on to more advanced courses. "Moving forward, RAPID U will provide increased visibility into clinical team readiness,” said Anil Singhal, MD, SVP, Worldwide Operations at iSchemaView. “This will allow an understanding of which modules are of particular interest, and move on to more advanced training as needed. Most importantly, this educational program will enable more members of the stroke care team to optimize RAPID in reducing the debilitating impacts of stroke.” Developed by leading stroke experts, RAPID technology has been selected for use in several groundbreaking trials that have changed treatment guidelines issued by both the American Heart Association and American Stroke Association. The RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID app or corporate partner workflow systems. For more information about RAPID U, contact training@rapid.ai.
featured-image

Press Release

Data Suggests New Guidelines in Stroke Care Have Led to Record Numbers of Patients Treated

Over 100% more mechanical thrombectomies indicated from 2017 to 2018, according to data from Rapid market intelligence Menlo Park, Calif. —May 15, 2019 – May is Stroke Awareness Month and in commemoration, iSchemaView, the worldwide leader in advanced imaging for stroke, is releasing its first market intelligence data from RAPID. The RAPID platform is designed to provide physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. Stroke afflicts around 800,000 Americans each year and ranks as the number five cause of death and the number one cause of disability in the United States. New RAPID data reveals that over 40,000 more patients’ lives were impacted in 2018 over 2017 via this advanced technology, more than doubling the number of patients scanned and thrombectomies indicated by imaging. iSchemaView’s RAPID has changed how physicians approach stroke care. From 2017 to 2018 there was over a 100% increase in patients imaged with RAPID worldwide (41,125 in 2017 and 82,365 in 2018). Perfusion imaging criteria was met for thrombectomy in 12,285 patients in 2017 and 25,269 in 2018. Based on the first quarter of 2019, RAPID is on pace to image over 132,500 patients in 2019 and identify over 40,000 potential patients for thrombectomies. The platform is also estimated to process over 250,000 total scans this year. While the above represents dramatic overall growth in patients addressed and thrombectomies indicated around the world, there was also significant same-site growth. Looking only at care sites active with the RAPID platform in 2017 as compared to the same sites in 2018, there was over a 50% growth in patients addressed (39,955 in 2017 and 60,821 in 2018), and potential thrombectomies indicated (11,811 in 2017 and 17,742 in 2018). This dramatic expansion in patients scanned tracks with new 2018 American Heart Association and American Stroke Association guidelines that have dramatically altered the management of acute stroke. These new guidelines were established after a series of studies were conducted and published by iSchemaView co-founder, Dr. Greg Albers and others. “RAPID has greatly impacted our ability to offer life- and disability-saving care to our patients,” said Cherylee Chang, M.D., medical director, Neuroscience Institute/Neurocritical Care at The Queen's Medical Center. “In 2017 we performed 37 thrombectomies; this increased to 93 in 2018 and we have already exceeded 30 cases in the first 3 months of 2019. Due to the ability of our stroke team, which includes our neurointerventionalists, to receive immediate results of RAPID’s perfusion imaging, our median door-to-puncture time is 46 minutes. RAPID has revolutionized stroke care.” “It is now just over a year since the simultaneous publication of DEFUSE 3 and the new 24-hour stroke treatment guidelines. Taking a look at the latest treatment numbers, it seems clear that the imaging-based studies have already made a huge impact on stroke care worldwide,” said Dr. Greg Albers, professor of neurology at Stanford University, director of the Stanford Stroke Center and co-founder of iSchemaView. “By building on the artificial intelligence and advanced imaging technology in RAPID, we will continue to contribute to increased treatment rates which will lead to a major reduction in stroke disability and mortality.”
featured-image

Press Release

RAPID now approved for use in Israel

iSchemaView expands RAPID’s worldwide reach and brings Israel the only clinically validated, next-generation imaging platform for assessing ischemic stroke Menlo Park, Calif. — April 9, 2019 – iSchemaView, the worldwide leader in advanced imaging for stroke, has received approval from AMAR (Israel’s Ministry of Health medical device regulation unit), for the use of the RAPID imaging platform across the State of Israel. This approval follows use and clearance of the iSchemaView RAPID technology across several of the founding Global Harmonization Task Force (GHTF) regions, including Australia, Canada, the United States and the EU. RAPID is designed to provide physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. Hospitals and clinics that treat ischemic stroke in Israel will now have access to RAPID’s automated CTP, MR, CTA and ASPECTS solutions, as well as their unique mobile app that accelerates the provision of information to support treatment decision making. RAPID’s expansion into Israel represents continued market growth across the Middle East, and is further confirmation that RAPID has become the de facto standard for stoke imaging around the world. “By having RAPID’s AI-powered imaging technology available in Israel we will be able to help tens of thousands of stroke suffering citizens in a way that was previously impossible,” says Simon Canham, iSchemaView Vice President & General Manager EMEA. “Moving forward we will be able to help better identify the best routes of care for patients, improving their chances of recovery and quality of life.” Developed by leading stroke experts, RAPID technology has been selected for use in several groundbreaking trials that have changed treatment guidelines issued by both the American Heart Association and American Stroke Association. The RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, SMS/MMS, the RAPID app or corporate partner workflow systems. Unique in the comprehensive depth and range of its clinical validation, RAPID is also the imaging standard in stroke research. iSchemaView’s imaging solution now has a research footprint across more than 300 stroke centers and more than 10 large-scale international clinical trials. RAPID has been shown to aid in the selection of patients in early and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND, and has been granted FDA clearance for selection of patients for both early and late window thrombectomy. The Complete RAPID Platform includes: RAPID MRI , which provides fully automated, easy to interpret diffusion and perfusion maps that identify brain areas with low ADC values, as well as delayed contrast arrival. RAPID MRI perfusion automatically quantifies regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds. RAPID CTP , which automatically quantifies regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds. Regions are color-coded and the volumes of interest are automatically measured. Maps (including mismatch maps) of the severity of Tmax delays are provided using a four-color-coded scale. RAPID CTA , which automatically provides clear, easy-to-interpret CTA maps that include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple, four-color-coded scale. Additionally, a 3D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles. RAPID ASPECTS , which automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. “With approval for RAPID in Israel we continue to greatly expand the number of health care facilities around the world that are able to assess stroke patients with the only clinically validated next-generation imaging technology,” said Don Listwin, CEO of iSchemaView. “Across the globe, stroke centers are now delivering over 250,000 RAPID cases a year. We are excited that we can bring RAPID to Israel and give more hospitals the tools they need to best help their patients and improve outcomes.” For more information about working with RAPID in Israel, contact Simon Canham at Canham@rapid.ai .
featured-image

Press Release

Dr. Gregory W. Albers Receives the Distinguished Clinical Research Achievement Award

Dr. Albers, Co-Founder of iSchemaView, led the Ground-Breaking DEFUSE 3 Study that Contributed to new American Heart Association and American Stroke Association Guidelines for Thrombectomy Washington, D.C. – March 6, 2019 – iSchemaView, the worldwide leader in advanced imaging for stroke care and research, is proud to announce that iSchemaView cofounder Dr. Gregory Albers has received the highly respected Distinguished Clinical Research Achievement Award, presented by the Clinical Research Forum. The Distinguished Clinical Research Achievement Awards are presented to the top two studies that show creativity, innovation, or a novel approach that demonstrates an immediate impact on the health and well-being of patients. In the DEFUSE 3 study, Dr. Albers and his team used iSchemaView’s RAPID™ advanced medical imaging platform, exclusively, to identify stroke patients who continue to have salvageable brain tissue many hours after stroke onset. By identifying patients who are most likely to benefit from stroke therapies, the DEFUSE 3 study is credited with accelerating the development and testing of new therapeutic options, as well as enabling hospitals to offer life-saving stroke therapies to many patients who arrive after the previous standard six-hour treatment window has elapsed. Dr. Albers is the Coyote Foundation professor of neurology and neurological sciences and professor, by courtesy, of neurosurgery at the Stanford University Medical Center. He is also director of the Stanford Stroke Center. Dr. Albers’ primary research focus is the diagnosis, management and prevention of ischemic stroke. He was instrumental in the development of RAPID, a medical imaging platform that allows physicians to identify stroke patients who have salvageable brain tissue. Due to the findings of DEFUSE 3 and other groundbreaking stroke studies that also employed RAPID, the American Heart Association and American Stroke Association changed their treatment guidelines for thrombectomy from six hours after onset to up to 24 hours after onset for patients with salvageable brain tissue. Following the awards ceremony, Dr. Albers will present the results of the DEFUSE 3 study to members of Congress and discuss the critical role of federal funding for clinical research. “My team and I are honored to receive the Distinguished Clinical Research Achievement Award,” said Dr. Albers. “It is incredibly gratifying to know that our findings have helped change the landscape for the diagnosis and treatment of ischemic stroke, leading to more patients being addressed, reducing disabilities and saving lives.” About the Top Ten Clinical Research Achievement Awards Recognizing the need to celebrate our nation's clinical research accomplishments that involve both innovation and impact on human disease, the Clinical Research Forum conducts an annual competition to determine the ten outstanding research accomplishments in the United States. These major research advances represent a portion of the annual return on the nation's investment in the health and future welfare of its citizens. About the Clinical Research Forum The mission of the Clinical Research Forum is to provide leadership to the national and clinical translational research enterprise and promote understanding and support for clinical research and its impact on health and healthcare. For more information, visit www.clinicalresearchforum.org.
featured-image

Press Release

iSchemaView Launches Rapid ANGIO

iSchemaView Partners with Siemens Healthineers to Integrate the Rapid Platform with syngo DynaCT to Deliver a Complete Imaging Solution for the Angio Suite. Menlo Park, Calif .—February 28, 2019 — iSchemaView, the worldwide leader in advanced imaging for stroke care and research, today announced RAPID ANGIO, a complete neuroimaging solution for the angiography suite that integrates iSchemaView’s RAPID software with syngo DynaCT Multiphase from Siemens Healthineers. The syngo DynaCT Multiphase is a state-of-the-art 3-dimensional image acquisition technique employing multiple rotations of a C-arm system to acquire a multiphasic 3D representation of the brain and its perfusion. This technology, when combined with the RAPID platform’s clinically validated CTP product, delivers a powerful imaging solution to the angio suite for acute stroke patients. “The RAPID ANGIO module, by combining the best-in-class syngo DynaCT system with the RAPID platform, allows for the direct evaluation of acute stroke patients in the angiography procedure room, saving precious time,” said Anil Singhal, MD, SVP, Worldwide Operations at iSchemaView. “RAPID ANGIO provides the most comprehensive real-time brain images for use in stroke treatment decisions, making this integration the most sophisticated angiography neuroimaging option available today.” The RAPID platform automatically provides clear, easy-to-interpret CT perfusion maps that readily identify brain regions with reduced cerebral blood flow and blood volume as well as delayed contrast arrival. It is the only neuroimaging platform FDA cleared for a thrombectomy indication. In addition to identifying irreversibly damaged brain tissue and salvageable areas, the CTP module includes HIR and CBV indices for the assessment of collateral blood flow and the rate of infarct growth, as well as a “golden hour” index for ultra-early patients. RAPID CTP helps physicians with patient triage and clinical decision making. “RAPID directly in the angio suite will help our specialists treat the right patients even faster,” said Professor Jian Ming Liu, Director of Neurosurgery Center, Changhai Hospital, China. “Having the most advanced RAPID technology available in both the radiology department and the operating theater provides the best options for our doctors and patients.” RAPID ANGIO runs on the RAPID Artificial Intelligence framework. Developed by leading stroke experts, the RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (ANGIO, CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID APP or corporate partner workflow systems.
featured-image

Press Release

iSchemaView's Rapid Approved for Use in Brazil

iSchemaView Expands RAPID's South American Footprint by Bringing Brazil the Only Clinically Validated, Next-Generation Imaging Platform for Assessing Ischemic Stroke Menlo Park, Calif .— February 21, 2019 – iSchemaView, the worldwide leader in advanced imaging for stroke, has received approval from ANVISA (the Brazilian Health Regulatory Agency), for the use of the RAPID imaging platform across Brazil. RAPID is designed to provide physicians with fast, fully automated, elegant and easy-to-interpret imaging that facilitates clinical decision-making around stroke. The approval comes after iSchemaView’s quality system was also certified through the Medical Device Single Audit Program (MDSAP) — a global approach to auditing and monitoring the manufacturing of medical devices, in an effort to improve safety and oversight on an international scale. Hospitals and clinics that treat ischemic stroke in Brazil will now have access to RAPID’s automated CTP, MR, CTA and ASPECTS solutions. RAPID’s expansion into Brazil represents significant market growth in South America, and is another sign that RAPID has become the de facto standard in stroke imaging around the world. “RAPID signifies the massive leaps medical technology has made in the last two years to better diagnose and treat stroke patients,” said Dr. Francisco Mont'Alverne, MD, PhD, Director of Interventional Neuroradiology Hospital Geral de Fortaleza. “This ANVISA clearance means hundreds of thousands of Brazilians may now benefit from RAPID's state-of-the-art, AI-powered imaging technology.” Developed by leading stroke experts, the RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID APP or corporate partner workflow systems. "Patients often arrive at the hospital several hours after stroke symptom onset," said Dr. Fabricio Oliveira Lima, MD, MPH, PhD, Director of the Stroke Unit Neurology Service Hospital Geral de Fortaleza. “RAPID allow us to see the status of the brain upon arrival and to quickly identify patients who are eligible for clot removal, even as late as 24 hours after stroke onset. This increases the chances for recovery for our patients, reduces disability and saves lives. The Complete RAPID Platform includes: RAPID MRI provides fully automated, easy to interpret diffusion and perfusion maps that identify brain areas with low ADC values, as well as delayed contrast arrival. RAPID MRI perfusion automatically quantifies regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds. RAPID CT perfusion automatically quantifies regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds. Regions are color coded and the volumes of interest are automatically measured. Maps (including mismatch maps) of the severity of Tmax delays are provided using a four-color-coded scale. RAPID CTA automatically provides clear, easy to interpret CTA maps which include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple, four-color-coded scale. Additionally, a 3D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles. RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. “Over 1,000 stroke centers in more than 40 countries across North America, South America, Europe, Asia and Australia have committed to using the RAPID platform for stroke imaging,” said Don Listwin, CEO of iSchemaView. “We are excited we can now bring RAPID to Brazil, give hospitals of all sizes the tools they’ve needed, and help address more patients than ever before. In addition, we have secured the support of some of the best RAPID experts in Brazil to provide clinical training.” For more information about working with RAPID in Brazil, contact info@irapid.com .
featured-image

Press Release

iSchemaView's Rapid Imaging Platform Chosen for Patient Selection in TIMELESS Trial

Used in a New Study to Evaluate the Efficacy and Safety of Tenecteplase Compared With Placebo in Patients with Acute Ischemic Stroke (AIS) Menlo Park, Calif . - February 6, 2019 — iSchemaView, the worldwide leader in advanced imaging for stroke care and stroke research, today announced that the company’s RAPID imaging platform has been chosen for use in determining subject eligibility for the “Thrombolysis in imaging eligible late window patients (4.5-24 hours) to evaluate the efficacy and safety of tenecteplase,” (TIMELESS) trial, which will evaluate the efficacy and safety of tenecteplase compared with placebo in patients with late window acute ischemic stroke (AIS). Genentech, a member of the Roche Group, sponsored the study Stroke is the third leading cause of death and primary cause of long-term disability in the United States. Acute ischemic strokes (AIS) account for 87 percent of all strokes. An ischemic stroke occurs when an obstruction, like a blood clot, blocks blood flow to the brain. The TIMELESS trial is designed to evaluate whether tenecteplase is safe and effective for use in AIS when administered between 4.5 and 24 hours after stroke onset. “Advanced imaging with RAPID was instrumental in changing the AHA guidelines for thrombectomy (mechanical reperfusion) and has the potential to be equally impactful for thrombolysis (chemical reperfusion),” said Mikayel Grigoryan, M.D., Medical Director of Neurointervention at Adventist Health Glendale Comprehensive Stroke Center. Unique in the comprehensive depth and range of its clinical validation, RAPID is now also the imaging standard in stroke research. iSchemaView’s imaging solution now has a research footprint across more than 300 stroke centers, more than 10 large-scale international clinical trials, and is being used clinically in over 800 hospitals worldwide. RAPID has been shown to aid in the selection of patients in early and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND, and has been granted FDA clearance for selection of patients for both early and late window thrombectomy. “The choice of iSchemaView for the TIMELESS study makes it clear: RAPID is the de facto standard for clinical trials in stroke,” said Carolina Maier, PhD, Vice President of Research at iSchemaView. “RAPID is the only imaging technology for stroke that has been clinically validated, which is why it has been used in such a broad range of clinical trials and why it is used in over 1,000 stroke centers worldwide.”
featured-image

Press Release

Pulsara and iSchemaView Unveil New Rapid Integration

Best-in-Class Partners Collaborate to Dynamically Share Critical Images in Real-Time with Stroke Teams Bozeman, Mont. & Menlo Park, Calif . — February 4, 2019 — Pulsara has expanded its integration strategy by partnering with iSchemaView, the worldwide leader in advanced imaging for stroke. By leveraging Pulsara's open API infrastructure, iSchemaView now streamlines the sharing of its RAPID imaging platform for stroke care collaboration globally. Pulsara’s seamless integration with iSchemaView is a natural fit with Pulsara’s stroke module. “Integration is key. From the outset, we built our platform on an open API infrastructure,” said James Woodson, Pulsara founder and CEO. “By working with iSchemaView, we’re coordinating with a premier partner who is aligned with similar vision and goals — to streamline care collaboration and better patient outcomes.” Pulsara is a novel mobile platform, developed by physicians, to improve the coordination and communication tasks essential to rapid assessment and care of patients suffering any timesensitive condition. Its specially-designed stroke workflow within the platform enables clinicians to share images, stroke scores, tPA contraindications and other specialized care information to enable stroke teams to communicate in the most efficient and timely manner. The integration between Pulsara and iSchemaView enables coordinated real-time sharing of iSchemaView’s RAPID images including CTP, MRI and CTA, with the entire stroke team. Clinicians and patients alike benefit greatly from strategic integrations like this. Improved workflows that allow for coordinated sharing of critical information further advance the vision of automated healthcare communications for entire regions. "Developed by leading stroke experts, RAPID combines unmatched expert features, proprietary algorithms and machine learning to deliver the best-in-class platform. By integrating with Pulsara, we are able to provide timely diagnosis information within a complete workflow package," said Don Listwin, CEO of iSchemaView. "With the power of the Pulsara platform, we can share real-time images with the right people at the right time to optimize patient outcomes." As stroke is a time-sensitive emergency, state-of-the-art tools that deliver immediate results provide the best chance of treatment success. The RAPID platform automatically provides clear, easy-to-interpret CT and MRI brain images indicating perfusion and angiographic blood flow abnormalities, that identify severely damaged tissue vs tissue at-risk. RAPID is the only neuroimaging platform that is FDA-cleared for selecting stroke patients for endovascular clot removal, also known as thrombectomy. “The patient journey goes beyond one ambulance, one hospital, one neurologist. It’s about connecting a time-sensitive team of clinicians all centered on the patient,” explained Kris Kaull, flight paramedic and chief marketing officer of Pulsara. “By partnering with iSchemaView, a company that is best in class, we are able to dynamically share critical information to key players with a simple tap.” ABOUT PULSARA Pulsara provides a real-time communication network across an entire region. The Pulsara platform, built on the power of mobile technology, unites the right clinicians at the right time for the right patient -- providing transparency and streamlined communication. Simply CREATE a dedicated patient channel. BUILD the team. And, COMMUNICATE using audio, video, instant messaging, data, images, and key benchmarks. Studies report an average decreased treatment time of nearly 30% when using Pulsara. Pulsara is the evidence-based standard of care. For more information, visit www.pulsara.com .
5 6 7 8 9